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Abstract
This study evaluated the adherence to prescribed cardiovascular therapy medications
among cardiovascular disease patients attending clinics in Misan, Amara, Iraq. Mixed meth-
ods were used to assess medication adherence comprising the Arabic version of the eight-
item Morisky Medication Adherence Scale (MMAS-8) and determination of drug concentra-
tions in patient dried blood spot (DBS) samples by liquid chromatography-high resolution
mass spectrometry. Three hundred and three Iraqi patients (median age 53 years, 50.5%
female) who had been taking one or more of the nine commonly prescribed cardiovascular
medications (amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, lisinopril, losartan,
simvastatin and valsartan) for at least six months were enrolled. For each patient MMAS-8
scores were determined alongside drug concentrations in their dried blood spot samples.
Results from the standardized questionnaire showed that adherence was 81.8% in compari-
son with 50.8% obtained using the laboratory-based microsample analysis. The agreement
between the indirect (MMAS-8) and direct (DBS analysis) assessment approaches to
assessing medication adherence showed significantly poor agreement (kappa = 0.28, P =
0.001). The indirect and direct assessment approaches showed no significant correlation
between nonadherence to prescribed cardiovascular pharmacotherapy and age and gen-
der, but were significantly associated with the number of medications in the patient’s treat-
ment regimen (MMAS-8: Odds Ratio (OR) 1.947, 95% CI, P = 0.001; DBS analysis: OR
2.164, 95% CI, P = 0.001). The MMAS-8 results highlighted reasons for nonadherence to
prescribed cardiovascular pharmacotherapy in this patient population whilst the objective
DBS analysis approach gave valuable information about nonadherence to each medication
in the patient’s treatment regimen. DBS sampling, due its minimally invasive nature, conve-
nience and ease of transport is a useful alternative matrix to monitor adherence objectively
in Iraq to cardiovascular pharmacotherapy. This information combined with MMAS-8 can
provide clinicians with an evidence-based novel approach to implement intervention
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Introduction
Cardiovascular diseases (CVD) cover disorders of the blood vessels and heart and include
hypertension, angina, heart attack, and stroke. Globally, CVD are a major cause of death,
accounting for 17.9 million deaths per year in 2016 representing 31% of the total deaths world-
wide [1]. In Iraq, non-communicable diseases, including CVD constitute a rising disease bur-
den after the 2003 war [2] and according to the World Health Organisation account for 27% of
all deaths in Iraq in 2016 [3].
Cardiovascular disease patients require lifelong treatment with a combination of medica-
tions including hypolipidemic drugs, antihypertensives, antiplatelet drugs, diuretics and anti-
coagulants. The most commonly prescribed CVD drugs in Iraq are amlodipine, atenolol,
atorvastatin, bisoprolol, diltiazem, losartan, simvastatin and valsartan [4]. A vital component
of managing CVD properly and ensuring treatment success is to ensure patients take their
medication(s) as prescribed. The drug selected and the dose prescribed should produce thera-
peutic drug levels in the patient’s bloodstream. Patient adherence to the prescribed pharmaco-
therapy helps ensure that the blood drug concentration is within the therapeutic limits in
order to improve clinical outcomes. Nonadherence to medications is documented to be a
major issue in situations where self-administration of oral medications is required [5] and in
situations where polypharmacy exists [6, 7]. There is evidence that as many as 50% of pre-
scribed CVD medications are not taken by patients as recommended [8–10]. This suboptimal
adherence to prescribed CVD therapies can lead to substantial health consequences for
patients and negative consequences for national healthcare systems because nonadherence
reduces the effectiveness of the drug treatment and is associated with morbidity, mortality,
medicines wastage, hospital admissions and higher costs of care [9, 11–13]. In USA, nonadher-
ence to prescribed drug therapy is the cause of approximately 125,000 avoidable deaths annu-
ally and accounts for $100-$300 billion annually in avoidable healthcare costs to their
healthcare systems [5]. Medication adherence is a multifaceted problem that can be influenced
by the interplay of patient, treatment and healthcare system-related factors [5]. In lower
income countries and middle-income countries, such as Iraq, the prevalence of substandard
and falsified medicines may exacerbate this healthcare problem by giving rise to unintentional
nonadherence [5, 14]. Given the high humanistic and economic cost associated with nonad-
herence to prescribed CVD pharmacotherapies the assessment of adherence is a crucial step to
ensure that clinicians make an informed clinical decision about treatment and that patients
derive the full benefits of the prescribed pharmacotherapy and reduce medicines wastage and
costs for healthcare services.
Currently, there is no “gold standard” method for assessing medication adherence in rou-
tine clinical practice but a multitude of methods have been employed since each method has
its advantages and limitations [5, 15]. These include indirect methods such as pill counts, ques-
tionnaires, patient diaries or self-reports, and prescription refill rates as well as direct methods
such as measurement of blood or urine drug or metabolite levels [16]. Indirect methods are
easy to use and low cost but cannot confirm if the patient has taken their medication correctly
and are proxy measures of medication adherence [16]. For instance, pill counts simply confirm
the number of tablets removed from their original container but cannot confirm if these tablets
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have been consumed by the patient. Furthermore, this assessment method provides no infor-
mation about the time a dose was taken which may be crucial in establishing clinical outcomes
[5]. One of the most commonly used standardized questionnaires to assess adherence to car-
diovascular therapy medications is the 8-item Morisky Medication Adherence Scale (MMAS-
8) [17–20]. Although widely used this self-administered validated tool can be subject to overes-
timation, recall bias and is unable to assess adherence to each medication in a patient’s treat-
ment regimen. Furthermore, it is unable to take into consideration drug pharmacokinetic and
pharmacodynamic parameters which vary from patient to patient. Direct assessment
approaches are more accurate methods of measuring medication adherence, however, current
measures are costlier in terms of both patient and clinician time and acquiring liquid blood
samples requires a visit to a clinic or hospital. The collection of urine samples is non-invasive;
however, some patient groups may be reluctant to provide this biosample due to religious, cul-
tural or ethical issues [21]. Tanna and Lawson postulate that the costs associated with direct
assessment can be reduced without detriment to the information produced, by use of a finger-
pick blood sample collected as a microsample such as a dried blood spot (DBS) for the deter-
mination of drug as a measure of medication adherence [21–23]. The ease of sample
collection, storage and transport coupled with presenting a low biohazard risk offered by
microsampling methods such as DBS mean that it is a viable option to objectively assess medi-
cation adherence especially in resource-limited settings [21, 24, 25]. Furthermore, it eliminates
the need of phlebotomy thereby facilitating self or remote collection of the DBS [26]. In Iraq,
only questionnaire-based assessment of adherence to antihypertensives has been conducted to
date and have shown nonadherence to these drug therapies to be prevalent [27, 28].
The aim of this study was to assess Iraqi patients’ adherence to treatment with atenolol,
amlodipine, atorvastatin, bisoprolol, diltiazem, lisinopril, losartan, simvastatin and valsartan
by using MMAS-8 coupled with the determination of these target cardiovascular medications
in DBS samples collected from the same patients and to compare the results between these two
assessment strategies.
Materials and methods
Study design and ethical approval
The study sample size was 303 and the sample size calculation was determined based on the
assumption that the prevalence of CVD in Iraq is 27%, which is close to the prevalence of
hypertension at 26.5% [29]. Cardiovascular disease prevalence in Iraq is not documented and
therefore the prevalence of hypertension was applied in the sample size calculation using the
Daniel equation [30]. Ethical approval for this study was obtained from the Ethics Committee
in Misan Health Directorate and De Montfort University’s Faculty of Health and Life Science
Research Ethics Committee.
Participants
Participants were recruited from Alsader Teaching Hospital and Misan Cardiac Centre in
Misan, Amara, Iraq during a routine clinical visit between July 2016 and March 2018. Eligible
participants were patients aged�18 years, and able to understand and communicate in Arabic,
had no visual or cognitive impairments and who had been prescribed one or more of the target
CVD medications for more than six months prior to recruitment. The target CVD medica-
tions were amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, lisinopril, losartan, simva-
statin and valsartan. Pregnant women and non-Arabic speakers, and participants that required
admission were excluded. The clinician (YO) screened patients during the study period by
applying the selection criteria when attending their appointment and assessed for eligibility. If
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eligible, the patients were invited to participate and directed to talk to the researcher (AA). The
researcher then re-checked the eligibility and those who agreed to participate were provided
information about the study by the researcher who gave each patient an Arabic participant
information leaflet and obtained written informed consent.
For each participant adherence to prescribed cardiovascular therapies was assessed in two
ways:
1. MMAS-8 adherence questionnaire
2. Collection of simple finger-prick blood samples and their subsequent analysis at De Mont-
fort University, UK.
MMAS-8 adherence questionnaire
Medication adherence was assessed using the structured and validated 8-item Morisky ques-
tionnaire, MMAS-8. A validated Arabic translated version of MMAS-8 was used in this study
since Arabic is the national language in Iraq. This questionnaire consists of eight questions,
the first seven items have a dichotomous answer (yes/no) that indicates adherent or non-
adherent behavior. The eighth item has a 5-point Likert scale indicating low to high level of
adherence. MMAS-8 total scores can range from 0 to 8 points. Using this standardized ques-
tionnaire scores equaling 8, 6 to<8, or <6, patients can be categorized as having high,
medium or low adherence to pharmacotherapy, respectively. The MMAS-8 adherence was
dichotomized where patients were classified as adherent or nonadherent instead of low,
medium and high adherence using a cutoff point of score 6 in MMAS-8. The validity of this
dichotomization has been previously published by the developer of the questionnaire [31].
Collection of patient blood spot samples and baseline medication
information
Prior to collection of the DBS samples each patient was required to supply baseline medication
data on the number and name of prescribed CVD medicines, dose, dose frequency, approxi-
mate time since last dose and name of other prescribed medications. This was via a mini CVD
drug prescription questionnaire translated in Arabic. This baseline information coupled with
CVD drug pharmacokinetic information would allow the researchers to establish if the calcu-
lated blood drug concentration was within the therapeutic window and if the patient had been
adherent or nonadherent [21].
Participant DBS samples were obtained by a simple fingerprick using a sterile lancet and
the drops of blood were collected on a Whatman 903 DBS sample collection card (GE Health-
care). Each DBS sample collection card was then allowed to dry at room temperature for 2–3
hours. After drying each card was stored in an individual labelled plastic re-sealable bag, con-
taining desiccant, and shipped to De Montfort University, UK under ambient conditions for
analysis.
Extraction and analysis of patient DBS samples
Solvent extraction of the target analytes from DBS was carried out using the protocol detailed
in our previously published work [32, 33]. The concentrations of amlodipine, atenolol, atorva-
statin, bisoprolol, diltiazem, lisinopril, losartan, simvastatin and valsartan in DBS extracts were
determined using a previously validated liquid chromatography-high resolution mass spec-
trometry (LC-HRMS) method on an Agilent 1290 LC coupled to an Agilent G6530A QTOF
mass spectrometer [32, 33]. This bioanalytical validation showed that all target analytes were
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stable in DBS samples for ten weeks at room temperature. All DBS samples collected in Iraq
were transported to the UK and analysed well within ten weeks of collection.
Adherence assessment based on the LC-HRMS analysis of DBS samples
Patients were considered nonadherent by DBS analysis when one or more of their prescribed
CVD medication concentrations were non-detectable or < 5.25% of published Cmax
or> published Cmax [21, 23].
Statistical analysis
Statistical analyses were conducted using SPSS software (Version 22.0. Armonk, NY: IBM
Corp). Qualitative variables such as gender and medications were expressed in terms of
median, interquartile range (IQR), frequencies and percentages. A confidence interval of 95%
was employed and a P-value of less than 0.05 was considered significant. A Chi-squared test
was used to examine the relationship between levels of nonadherence and gender. Logistic
regression was used to examine the relationship between the levels of nonadherence as mea-
sured by MMAS-8 and DBS analysis and patients’ age, number of medications each patient is
prescribed and the number of different medication tablets taken by each patient. The Kappa
concordance test was used to measure the degree of agreement between adherence classified
by MMAS-8 and DBS analysis. Mean and standard deviation values were used to express the
concentrations of the target CVD medications in the DBS samples for individual patients.
Results and discussion
Patient characteristics
A total of 303 participants fulfilled the inclusion criteria of which 49.5% were male and 50.5%
female. The median age of the patients was 53years ranging between 30 and 69 years and the
median number of medications per regimen was 3 (Table 1). Data on the CVD medications
prescribed to patients are presented in Table 2. In this sample 31.1% of the patients were pre-
scribed β-blockers, 25.5% angiotensin II receptor blockers, 16.7% an ace inhibitor, 15.5% stat-
ins and 11.2% calcium channel blockers. Bisoprolol (17.5%) was the most widely prescribed
medication followed by lisinopril (16.7%) and valsartan (14.8%). Amlodipine (3.4%) and ator-
vastatin (4.1%) were the least prescribed medications in this cohort.
Adherence assessed using MMAS-8 questionnaire
The MMAS-8 adherence questionnaire scores ranged from 0 to 8. Based on their MMAS-8
score, patients from the Iraqi cohort were categorized into three groups as described in the
methods section: low adherence (MMAS-8 score < 6), medium adherence (MMAS-8 score 6
to< 8) or high adherence (MMAS-8 score 8). As shown in Table 3 more than half of the par-
ticipants (54.1%) exhibited high adherence, 27.7% exhibited medium adherence and 18.2%
exhibited low adherence. In this study patients were classified as adherent or nonadherent
rather than low, medium and high using a score of 6 as the cut-off point [31, 34]. Thus 248 par-
ticipants (81.8%) were adherent to their prescribed CVD pharmacotherapy of which 125 were
male (50.4%) and 123 were female (49.6%). The proportion of nonadherent patients, as deter-
mined by MMAS-8, was 55 participants (18.2%) of which 25 were male (45.5%) and 30 females
(54.5%). This level of nonadherence was similar to a previous questionnaire-based adherence
assessment study conducted in Iraq where the reported level of nonadherence was 19.6% [28].
However, it was significantly lower than another questionnaire-based study conducted in Iraq
[27]. Adherence to prescribed drug therapy is a complex multifactorial problem that can be
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influenced by the interrelationship of various factors including patient factors, treatment fac-
tors and healthcare system factors [5]. MMAS-8 is unable to assess adherence to multiple med-
ications in the prescribed pharmacotherapy regimens and the assessment of adherence by
Table 2. Prescribed CVD medications in the Iraqi cohort.

















Table 1. Patient population sample characteristics (N = 303).
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MMAS-8 is subject to overestimation because this is dependent on the total score obtained
from a given patient’s response to the questions. It is possible that patients overestimated their
adherence in the current study to a greater degree than in previous studies where lower levels
of adherence were documented using a questionnaire-based assessment.
There was no significant relationship between the level of nonadherence assessed by
MMAS-8 and gender (Chi squared = 0.441, df = 1, P = 0.507) and MMAS-8 and age (Odds
Ratio (OR) 0.923, 95% CI, P = 0.484). A significant positive correlation between nonadherence
and number of medications prescribed (OR 1.947, 95% CI, P = 0.001) and the number of tab-
lets of different medications taken by each patient (OR 1.436, 95% CI, P = 0.001) was shown.
As the number of medications taken by a patient increased, the possibility of nonadherence
also increased. In the nonadherent group, the mean number of medications taken by patients
was 6.53 ±1.63 in comparison with 3.38 ±2.07 in the adherent group.
Based on participant responses to the MMAS-8 questions, 72.3% of nonadherent partici-
pants were intentionally nonadherent to their CVD medication. The main reasons for this
were medication-related side effects (93.6%), inconvenience of taking the medication (85.1%),
financial cost of medications and patients’ belief. The participants reported reasons for medi-
cation-related inconvenience were complexity of the regimen, dose frequencies and patient-
clinician discordance. Adherence to prescribed drug therapies may be improved by the use of
simplified treatment regimens and by reducing the frequency of administration. Patients may
prefer medications that require administration on a once daily basis, prescribing the maximum
number of doses possible at one time and thus limiting the frequency at which treatment is
required. Swapping medications may cause confusion and is inconvenient, and may result in
nonadherence [35]. 70.9% of nonadherent patients gave no reason for their refusal to take
their medications. By comparison, 27.3% of participants were unintentionally nonadherent
and the main reasons for this were forgetfulness and poor understanding of disease.
Adherence assessed using drug concentrations determined in patient DBS
samples
Adherence to a prescribed drug therapy is indicated by the drug level in the blood being
between the published Cmax concentration and 5.25% of Cmax i.e. the drug concentration after
5 half-lives, when it is considered to be therapeutically inactive. Conversely, nonadherence is
indicated by the absence of the drug in the volunteer’s DBS sample or if the drug level deter-
mined is outside its therapeutic window [21, 23]. The assessment of nonadherence by determi-
nation of the target drug concentration by LC-HRMS analyses of DBS samples from the same
volunteers that completed the MMAS-8 questionnaire showed that 154 (82 male and 72
female) patients (50.8%) were adherent to their prescribed CVD medications and 149 (68 male
and 81 female) patients (49.2%) were nonadherent. This level of nonadherence is in line with
the 50% figure reported by the WHO for nonadherence to medications for chronic illnesses in
developed countries [36]. Table 4 gives the breakdown of adherence and nonadherence to
each target CVD drug amongst the study participants using the objective patient DBS analysis
data. This revealed that nonadherence to the target CVD medications was not uniform.
Table 3. Adherence amongst Iraqi CVD patients assessed using MMAS-8 score.
Adherence level (score) Total study population (N = 303)
N %
Low adherence (< 6) 55 18.2
Medium adherence (6 - < 8) 84 27.7
High adherence (= 8) 164 54.1
https://doi.org/10.1371/journal.pone.0251115.t003
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Previous adherence assessment studies in Iraq used indirect methods only and this is the first
study to report the use of a direct and objective method to assess adherence to prescribed CVD
pharmacotherapy. Thus, there is no previous data about the level of adherence found by direct
methods to compare with in Iraq.
All target analytes in the Iraq collected DBS samples were considered stable since all DBS
samples were analysed within the validated ten-week stability period [32, 33]. Furthermore, all
target analytes from the Iraq patient DBS samples plus quality control (QC) DBS samples
within each analytical run were within 15% of their baseline concentration and therefore con-
sidered stable.
Adherence assessed using drug concentrations in the biological microsample revealed that
gender (Chi squared = 1.707, df = 1, P = 0.185) and age (OR 0.856, 95% CI, P = 0.321) were
not significantly associated with the level of nonadherence to prescribed CVD pharmacother-
apy. Analogous to the MMAS-8 evaluation, there was a significant positive correlation between
with the number of medications in the patient’s prescribed treatment regimen (OR 2.164, 95%
CI, P = 0.001) and the number of different tablets taken by each patient (OR 1.607, 95% CI,
P = 0.001).
In Table 4 the number of nonadherent patients were categorized in the following three catego-
ries: (i) the number of patients with no detectable drug i.e. with drug concentration below the
limit of quantification (LOQ); (ii) the number of patients with drug concentration in between the
LOQ and 5.25% of the drug Cmax; (iii) the number of patients with drug concentration>Cmax.
Ingestion of a medication and LC-HRMS analysis showing non-detectable drug in a patient’s
DBS sample is a strong indicator that the patient is likely to have ingested a substandard and/or
falsified medicine and was therefore unintentionally nonadherent [5]. In Table 4 the majority of
nonadherent patients are in this category. Drug concentrations in between the LOQ and 5.25% of
the drug Cmax would indicate that the patient may be taking their medication but may be skipping
doses. No patients in this study were in this category. Drug concentrations>Cmax indicate that
the incorrect medication dose has been taken and four patients were in this category.
Comparison of medication adherence assessments: MMAS-8 and dried
blood spot analysis
To assess the agreement and disagreement between MMAS-8 and blood microsample analysis
approaches, the determination of drug concentration in the DBS microsamples was considered






No. of adherent patients (%) No. of nonadherent patients (%)
Patients with no detectable
drug concentration <LOQ
Patients with drug concentration in
between the LOQ and 5.25% of Cmax
Patients with drug
concentration > Cmax
• Drug concentration in
between 5.25% of Cmax
and < Cmax
Amlodipine 0.5 10(66.7) 5(33.3) - -
Atenolol 10 46(78.0) 9(15.3) - 4(6.7)
Atorvastatin 0.5 8(44.4) 10(55.6) - -
Bisoprolol 0.1 57(74.0) 20(26.0) - -
Diltiazem 0.5 20(58.8) 14(41.2) - -
Lisinopril 0.1 48(65.8) 25(34.2) - -
Losartan 5 22(46.8) 25(53.2) - -
Simvastatin 0.1 24(48.0) 26(52.0) - -
Valsartan 50 33(50.8) 32(49.2) - -
https://doi.org/10.1371/journal.pone.0251115.t004
PLOS ONE Assessment of medication adherence in Iraqi patients with cardiovascular disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0251115 May 14, 2021 8 / 15
to represent the ‘true’ classification of medication adherence. Thus, 248 participants were clas-
sified as adherent by MMAS-8 (score > 6). However, DBS analyses showed that only 146
(58.9%) of these 248 participants were actually adherent since their CVD drug blood concen-
trations determined were between 5.25% of Cmax and Cmax, the other 102 participants (41.9%)
were deemed nonadherent. This suggests the likely overestimation of medication adherence
by MMAS-8 for the 102 participants.
Fifty-five participants were classified as nonadherent by MMAS-8, with 47 (88.5%) of these
participants confirmed as being nonadherent according to their DBS drug concentrations. The
other eight participants (14.5%) were confirmed as being adherent by DBS analysis. This dis-
crepancy may be explained by the acquiescence bias response where the participants give affir-
mative answers regardless of the content of the question, and where the chances of this form of
bias becoming apparent in self-reported questionnaires is quite high [37]. Affirmative answers
in MMAS-8 take a value of zero. Thus, the total score will classify patients as being nonadher-
ent. The eight participants who were classified adherent by the DBS analysis responded “YES”
to all MMAS-8 questions and thus scored zero.
The agreement between the two approaches to assessing CVD medication adherence was
tested via the kappa test, which showed only slight agreement (kappa = 0.28, P = 0.001). This
result is different to those reported in other studies which showed that questionnaires were
generally highly concordant with biosample drug level measurements [38, 39]. However, these
studies either used statistical analysis, such as the Pearson coefficient, which is not recom-
mended for assessment of agreement between two approaches, or used an arbitrary cut-off
point in the kappa test. For clinical studies it is recommended that a kappa of 0.8 should be
used as a minimum acceptable value for agreement [40].
As is shown in Table 5, agreement and disagreement between MMAS-8 and DBS analyses
for each CVD medication showed high agreement for atenolol and bisoprolol at 88.1% and
87.0% respectively, and high disagreement for simvastatin and atorvastatin at 52.0% and 50.0%
respectively. However, the overall agreement for nonadherence to prescribed CVD pharmaco-
therapy as assessed by the kappa test showed only slight agreement between the two
approaches (kappa = 0.28, P = 0.001).
Both assessment approaches showed no correlation between the level of adherence with
respect to gender and age. In the literature, there are conflicting results about the correlation
between adherence to CVD medications and gender suggesting that complex behavioral fac-
tors and sociological gender-based dynamics are at play [4]. The lack of correlation between
age and nonadherence to CVD medications is not in line with the findings of another study
Table 5. Agreement and disagreement of nonadherence assessment to prescribed CVD pharmacotherapy between
MMAS-8 and DBS analysis.
CVD
medication
Agreement between MMAS-8 and DBS
analysis (%)
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[34]. Possible reasons for this difference could include various Iraq-specific factors such as the
fact that there are no guidelines for the management of CVD in Iraq; there are no CVD medi-
cation counselling centres or free healthcare schemes and there is an absence of social support
programmes offering appropriate support in Iraq. Thus, nonadherence to prescribed CVD
medications might well be expected to affect all age groups in this study. However, the direct
and indirect adherence assessment methods employed in this study both showed a significant
positive correlation between the level of nonadherence measured and the number of medica-
tions taken.
In line with previous studies [41, 42] these results show that regimen complexity and num-
ber of prescribed medications influence adherence to prescribed pharmacotherapy. Logistic
regression indicated a significant positive correlation between nonadherence assessed by
MMAS-8 and the number of medications prescribed (OR 1.947, 95% CI, P = 0.001). As the
number of prescribed medications for a patient increased, the possibility of nonadherence to
prescribed drug therapy increased accordingly. In the nonadherent patient group, the mean
number of prescribed medications was 6.53 ± 1.63 in comparison with 3.38 ± 2.07 in the
adherent group. There was also a significant positive correlation between the medication non-
adherence assessed by DBS analysis and the number of medications in the prescribed regimen
for a patient (OR 2.164, 95% CI, P = 0.001). The mean (±SD) of medications in the nonadher-
ent patients was 5.46 ± 2.15, compared to 2.50 ± 1.40 in the adherent group. Polypharmacy is
common practice to control CVD [6, 7] and to improve mortality and morbidity, however it
can expose patients to increased risk of adverse drug reactions and drug-drug interactions [43]
and is a known contributor to intentional medication nonadherence [5]. The prevalence of
substandard and falsified medications in the markets of developing countries such as Iraq
could also account for the unintentional nonadherence to prescribed drug therapy and the dif-
ferences in levels of nonadherence for the different medications [5, 14]. It is postulated that if a
patient ingests such poor-quality medicines their blood drug levels will not reach the required
therapeutic levels since such medications contain little no active pharmaceutical ingredient
and this can lead to treatment failure [5, 14].
Whilst MMAS-8 is easy to administer to patients it is unable to track nonadherence to each
medication in the regimen. Since polypharmacy is common in the treatment of CVD this is a
drawback of using this type of indirect assessment method for evaluating adherence to drug
therapy. Furthermore, when these indirect methods are employed to assess medication adher-
ence it is not possible to track dosing error and/or prescription error or if the patient took the
medication at the wrong time. Patients may take the wrong medication or the incorrect dose
or at the wrong time. In these cases, whilst the medication-taking behavior is present the
patient will not derive maximum therapeutic benefit from the ingested medication or may
experience adverse side effects. Such indirect methods of assessment cannot also take into con-
sideration patient-to-patient variation in pharmacokinetics, pharmacodynamics and pharma-
cogenetics, which affect drug concentrations in the blood. If a clinician assumes that a patient
is taking their prescribed medicine as recommended, he or she may attribute progression of
the patient’s CVD condition to a lack of activity of the prescribed CVD drug and therefore
may unnecessarily change a regimen [5]. As is evident from Fig 1 the direct assessment
method of using the analysis of blood microsamples is able to provide information about the
drug concentrations of each drug and thus nonadherence for each medication. This objective
information would be helpful to clinicians in terms of optimizing and individualizing each
medication in the regimen for each patient. For instance, one patient in this study was pre-
scribed losartan and simvastatin and was categorized as adherent according to his/her MMAS-
8 score. However, the LC-HRMS analysis of their DBS sample showed that this patient was
only adherent to losartan but not simvastatin and interventions were put in place by the
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clinician to address this issue. Furthermore, MMAS-8 alone cannot also determine if the
patient took the correct dose at the recommended time. For instance, four patients in this
study were prescribed atenolol and were categorized as adherent based on MMAS-8, however,
three of these patients were deemed nonadherent based on DBS analysis as their blood atenolol
concentrations exceeded the Cmax for the reported dose of atenolol (50 mg and 100 mg). Sub-
sequent patient discussions with the clinician revealed that all three patients had taken more
than the prescribed dose in the belief it would lead to improved clinical outcomes. The fourth
patient had mistakenly inserted his/her atenolol blister pack in their atorvastatin packaging
and so had been taking double the dose of atenolol whilst missing his/her dose of atorvastatin.
This explained the high concentration of atenolol and the non-detection of atorvastatin in the
DBS sample taken from this patient. In these four situations atenolol tablets were ingested by
each of the patients and each patient responded honestly to the MMAS-8 questions but these
patients were taking the incorrect dose of atenolol, which MMAS-8 is unable to reveal. The
objective assessment of medication adherence using quantitative dried blood spot analysis fits
into the framework of personalised medicine and would offer a less costly and more direct
approach than genetic analysis for personalised titration of pharmacological interventions.
The dual approach of employing indirect and direct methods to measure medication adher-
ence can help healthcare providers to accurately assess adherence and identify barriers associ-
ated with nonadherence to prescribed drug therapy. The healthcare providers can then
attempt to address the associated problems and inform the patient as to how the problem will
be addressed. Triangulation with other methods such as patient interviews could provide addi-
tional information.
Fig 1 and Table 4 indicate that nonadherence to CVD medications, in the Iraqi patient
cohort, as assessed by DBS analysis is not uniform. Differences in the levels of adherence to
prescribed CVD pharmacotherapy can be influenced by the medication class and medication-
Fig 1. A comparison of nonadherence assessment to prescribed CVD pharmacotherapy between DBS analysis and MMAS-8.
https://doi.org/10.1371/journal.pone.0251115.g001
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related side effects. Statins are documented to have lower adherence levels compared to other
CVD medications [44]. This study supports these findings where the adherence to atorvastatin
and simvastatin was 44.4% and 48.0% respectively versus 78.0% and 74.0% for the two β-block-
ers, atenolol and bisoprolol respectively. Availability and cost of medications in Iraq could also
account for the differences seen in adherence levels for the CVD drugs. In Iraq, atorvastatin,
simvastatin and valsartan have a relatively high retail price in comparison with atenolol and
bisoprolol. Furthermore, at the time of this study, these statins were only available to patients
from the Iraq private healthcare sector. Medication availability in the Iraq public healthcare
sector is dependent upon demand of each medication and can change annually. The Iraq pri-
vate healthcare sector has higher retail prices for all medications compared to the public and
intermediate sectors where medication prices are controlled by the Iraq Ministry of Health [4].
Conclusion
This is the first study to assess adherence to prescribed cardiovascular pharmacotherapy in
Iraq via drug concentrations in DBS samples and comparing to MMAS-8 results. This study
showed that only 50.8% of the Iraqi volunteers were adherent to one or more of their pre-
scribed CVD medications when assessed using the analysis of patient DBS samples in this
patient population. This compared with 81.8% of adherence determined by MMAS-8 suggest-
ing that the assessment of adherence using a standardized questionnaire may be subject to a
degree of overestimation. Poor agreement between the two assessment approaches was evident
and the DBS derived data provided drug specific information about patient medication taking
behavior and revealed that nonadherence was not uniform towards the different medications
in the patient drug regimens.
The unique mixed method approach investigated in this study is a very useful approach to
adherence assessment in providing an evidence-base to clinicians to make informed clinical
decisions for future treatment and intervention(s) development and maximise patient clinical
outcomes. The minimally invasive DBS microsample collection method used in this study
offers advantages of patient convenience and ease of storage for routine implementation in
Iraq. A further benefit of this patient-friendly sample collection method is that the DBS sam-
ples can be easily shipped for analyses to laboratories outside Iraq where sophisticated hyphen-
ated mass spectrometry-based systems, required for analyses, are readily available [45]. The
direct blood drug concentration method can provide objective information on the levels of
each medication in the patient’s blood, thus offering a route for optimization and personalisa-
tion of treatment, whilst the indirect standardized questionnaire method highlights possible
reasons for nonadherence to prescribed CVD pharmacotherapy. In the event of poor patient
progress, it is essential the clinician knows if the patient has followed the prescribed treatment
regimen as recommended and clinicians need an evidence-based framework to guide their
clinical decisions. The specific medication-related nature of the blood concentration data can
aid the clinician to make informed clinical decisions about future treatment and results from
the MMAS-8 questionnaire can aid the clinician to initiate evidence-based discussions with
the patient to understand exactly the reasons for nonadherence.
The findings of this study also raised another critical healthcare issue for Iraq which is the
evidence of the high risk of substandard and/or falsified medicines circulating within the Iraqi
healthcare system and unknowingly being made available to patients.
Cardiovascular diseases are a growing healthcare concern in Iraq and the low level of adher-
ence to prescribed CVD pharmacotherapy highlighted in this study requires actions for phar-
maceutical care. This study provides the impetus for assessment of medication nonadherence
in routine clinical practice in Iraq, using a mixed method approach. This is to maximise
PLOS ONE Assessment of medication adherence in Iraqi patients with cardiovascular disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0251115 May 14, 2021 12 / 15
patient benefit from the drug therapies prescribed and reduce medicines wastage and health-
care provider costs.
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